U.S. Centers Seek Namodenoson for Pancreatic Cancer Compassionate Use
U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.
Experimental drug could spur immunotherapy response in patients with non-small cell lung cancer
